Semaglutide at 3 Months: the real-world timeline

Step 1: How the dosing sequence unfolds over the first three months

Semaglutide for weight management does not start at full strength. The licensed schedule (described in the NHS medicines guidance on semaglutide) begins at 0.25mg weekly for a month, then 0.5mg, then 1mg, with the aim of reaching the 2.4mg maintenance dose by around week 17. Three months in, many people are mid-ladder, somewhere between 1mg and 1.7mg depending on tolerability and their prescriber's clinical judgement.

That pace is deliberate. Starting low gives your digestive system time to adapt to slower gastric emptying. Nausea, which is the most commonly reported side effect, tends to be sharpest immediately after a dose increase and fades over the following days. By month three most people report that their system has found a rhythm, appetite suppression feels steadier, and the early nausea is largely behind them.

One practical note: the titration schedule does not always line up neatly with calendar months. If you order mid-month, go on holiday, or your delivery lands on a bank holiday, the timing shifts slightly. Plenty of people find that ordering just before payday or at the start of the month keeps the routine predictable. None of that changes the clinical sequence, the prescriber's timeline runs from your start date, not the calendar.

For a fuller picture of the early weeks before the three-month point, the two-month Wegovy timeline covers what most people notice between weeks four and eight.

Step 2: What the evidence says about weight loss at this stage

Clinical trial data rarely reports specifically at the twelve-week mark, because trials are designed around longer endpoints. What the STEP 1 data shows is a clear downward trajectory that steepens once the maintenance dose is reached. At month three, with most participants still below 2.4mg, weight loss is typically in early progress, meaningful but not the full picture of what the medicine can do.

Average figures from the trial (roughly 15% body weight reduction over 68 weeks) tell you about the destination, not the three-month checkpoint. Individual variation is wide. Factors including starting weight, diet, activity levels and whether comorbidities are present all influence how much has shifted by week twelve. A smaller loss at three months does not mean the medicine is not working; it may simply mean the most effective dose has not yet been reached.

The phase 3 evidence for semaglutide sets out the trial data in more detail for anyone who wants to go deeper on the numbers. At month three, the more useful question is usually whether appetite suppression is present, whether side effects are tolerable, and whether the prescriber is satisfied with progress, not whether a specific percentage has been hit.

Step 3: Side effects at three months and when to seek help

By the three-month stage, the side-effect profile has usually settled compared with weeks one to four. Nausea, the most common complaint, tends to peak around dose increases and diminish between them. Constipation, loose stools and indigestion are still reported but typically at lower intensity than in the first month.

Some things do not settle and should prompt urgent medical attention. Severe stomach pain that radiates to the back (with or without vomiting) can be a sign of pancreatitis, which the MHRA highlighted as a known but infrequent risk in a Drug Safety Update issued in January 2026. Gallbladder symptoms (sharp pain in the upper right abdomen, especially after eating), signs of an allergic reaction, and significant dehydration from persistent vomiting or diarrhoea all warrant prompt medical contact.

If something feels wrong at month three, the right step is to contact your prescribing service. At nume, clinical aftercare runs seven days a week, you are not on your own between repeat orders. You can also report suspected side effects directly using the MHRA Yellow Card scheme.

Step 4: Whether to continue, pause or switch at the three-month point

Three months is a natural review point. NICE guidance on semaglutide notes that continuing should be reconsidered if weight loss is under 5% after six months at the maintenance dose, so month three is not a formal clinical threshold, but it is a sensible moment to take stock.

Some people at this stage are considering whether to continue with semaglutide or explore other options. The semaglutide overview and the broader Wegovy treatment page explain the licensed indications and eligibility criteria. For those thinking about cost and what a longer course looks like financially, the Wegovy cost page gives factual context on private pricing.

If you are weighing up what six months of treatment might look like from here, the six-month Wegovy timeline picks up where this page leaves off. And if you are considering whether this treatment is right to start, or to restart, the team at our treatment consultation page is the place to check your eligibility with a GPhC-registered prescriber.